Lúcia Santos

Lúcia Santos

Auto-generated profile, based on publicly available information

Lúcia Santos

Department of Physiology, University College Cork, Cork T12 K8AF, Ireland

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 July 2024 in Science
Verified
Journal Article
Open access
AWAaron Weimann
Aaron Weimann
ADAdam M. Dinan
Adam M. Dinan
CRChristopher Ruis
Christopher Ruis
ABAudrey Bernut
Audrey Bernut
SPStéphane Pont
Stéphane Pont
RFR. Andres Floto
R. Andres Floto
The major human bacterial pathogenPseudomonas aeruginosacauses multidrug-resistant infections in people with underlying immunodeficiencies or structural lung diseases such as cystic fibrosis (CF). We show that a few environmental isolates, driven by horizontal gene acquisition, have become dominant epidemic clones that have sequentially emerged and spread through global transmission networks over the past 200 years. These clones demonstrate varying intrinsic propensities for infecting CF or non-CF individuals (linked to specific transcriptional changes enabling survival within macrophages); have undergone multiple rounds of convergent, host-specific adaptation; and have eventually lost their ability to transmit between different patient groups. Our findings thus explain the pathogenic evolution ofP. aeruginosaand highlight the importance of global surveillance and cross-infection prevention in averting the emergence of future epidemic clones.

21 May 2019 in Genes
Verified
Journal Article
Open access
PDF file
KMKaren Mention
Karen Mention
LSLúcia Santos
Lúcia Santos
PHPatrick Harrison
Patrick Harrison
Cystic fibrosis (CF) is a monogenic autosomal recessive disorder caused by mutations in the CFTR gene. There are at least 346 disease-causing variants in the CFTR gene, but effective small-molecule therapies exist for only ~10% of them. One option to treat all mutations is CFTR cDNA-based therapy, but clinical trials to date have only been able to stabilise rather than improve lung function disease in patients. While cDNA-based therapy is already a clinical reality for a number of diseases, some animal studies have clearly established that precision genome editing can be significantly more effective than cDNA addition. These observations have led to a number of gene-editing clinical trials for a small number of such genetic disorders. To date, gene-editing strategies to correct CFTR mutations have been conducted exclusively in cell models, with no in vivo gene-editing studies yet described. Here, we highlight some of the key breakthroughs in in vivo and ex vivo gene and base editing in animal models for other diseases and discuss what might be learned from these studies in the development of editing strategies that may be applied to cystic fibrosis as a potential therapeutic approach. There are many hurdles that need to be overcome, including the in vivo delivery of editing machinery or successful engraftment of ex vivo-edited cells, as well as minimising potential off-target effects. However, a successful proof-of-concept study for gene or base editing in one or more of the available CF animal models could pave the way towards a long-term therapeutic strategy for this disease.

1 January 2022 in Journal of Cystic Fibrosis
Verified
Journal Article
Closed access
LSLúcia Santos
Lúcia Santos
KMKaren Mention
Karen Mention
KCKader Cavusoglu-Doran
Kader Cavusoglu-Doran
DSDavid J. Sanz
David J. Sanz
MBMafalda Bacalhau
Mafalda Bacalhau
Carlos FarinhaCarlos Farinha
Carlos Farinha

25 July 2025 in Expert Opinion on Pharmacotherapy
Verified
Journal Article
Closed access
LSLúcia Santos
Lúcia Santos
MCMariana Camargo
Mariana Camargo
Vito TerlizziVito Terlizzi
Vito Terlizzi
Miquéias Lopes-PachecoMiquéias Lopes-Pacheco
Miquéias Lopes-Pacheco
Cystic fibrosis (CF) treatment has been transformed by CF transmembrane conductance regulator (CFTR) modulator therapies, yet significant gaps remain for those with non-responsive or modestly responsive (below therapeutically relevant levels) genotypes and advanced disease. Emerging agents for genetic therapies and targeting symptoms are in development and offer hope for broader, more durable clinical benefits. This review synthesizes the latest clinical advances aiming to shape the future of CF care. We examine investigational agents in clinical development, including: alternative CFTR modulators (e.g. potentiators, correctors, and amplifiers); gene-based therapies utilizing viral and non-viral vectors; anti-inflammatory approaches; and infection-targeted therapies. Clinical trial data and combination strategies are discussed. Despite dramatic improvements in clinical outcomes and survival in PwCF on modulator drugs, further efforts are warranted for ineligible/non-responsive individuals or intolerant to modulators. In addition, it remains vital to identify novel therapeutic strategies to mitigate lung damage and disease progression as infection and inflammation persist even in PwCF receiving 'highly effective' modulator therapy.

16 October 2022 in Science Reviews. Biology
Verified
Journal Article
Open access
LSLúcia Santos
Lúcia Santos
This year marks the 10th anniversary of the CRISPR/Cas9 genome editing discovery. Since its discovery in 2012, the CRISPR/Cas9 system has become an indispensable tool in many research fields. This system has been extensively characterized and further optimized to broaden its editing capabilities. Depending on the DNA modification to make, there are now available several editing agents. In this review, we provide an overview of the CRISPR/Cas9 system and how it can be used to fix the DNA using the traditional repair mechanisms non-homologous end joining (NHEJ) and homology-directed repair (HDR), and the most recent gene editing approaches – base editing and prime editing.